The Texas Fentanyl Crisis in Numbers

The Texas Workforce Commission's One Pill Kills campaign — launched in collaboration with Governor Abbott's office — has documented what the Texas Department of State Health Services (DSHS) data confirms year over year: fentanyl has become the dominant driver of drug poisoning deaths in Texas, displacing all other substances at a pace no public health response fully anticipated. According to DSHS and the Texas Overdose Data to Action (TODA) program, fentanyl accounted for just 11.5% of all fatal drug poisonings in Texas in 2019. By 2022, that share had risen to 44.6%.

From 2019 to 2022, fentanyl-related deaths in Texas increased by more than 500%, rising from 317 to 2,012 confirmed deaths. By the 12-month period ending mid-2024, the state recorded over 1,900 fentanyl poisoning deaths — an almost 20% decrease from the prior year's 2,360, representing the first meaningful decline after five consecutive years of increases.

Why Standard Opiate Panels Miss Fentanyl

Here is the clinical reality that every Texas recovery center must understand: a standard opiate (OPI) immunoassay panel does not detect fentanyl. The opiate analyte on most 5-panel, 10-panel, and even some 12-panel urine cups is calibrated to detect morphine and codeine metabolites — not fentanyl or any of its analogs. A resident or client who has been using illicitly manufactured fentanyl, which now contaminates the drug supply across Texas in counterfeit pills, powder, and mixed street drugs, will screen negative on a standard opiate panel and appear clean.

This is not a theoretical risk. An estimated 45% of all drug-related deaths in Texas from August 2022 to August 2023 involved fentanyl. The contamination of the illicit drug supply is widespread and indiscriminate — fentanyl has been found mixed with cocaine, methamphetamine, heroin, and counterfeit prescription pills. A Texas recovery program that screens clients with a standard panel and no dedicated fentanyl analyte is operating with a detection gap that directly endangers patient safety.

Choosing the Right Fentanyl-Detecting Cup for Your Texas Recovery Program

For Texas recovery centers building or upgrading their drug testing protocols, the fentanyl-aware urine cup is no longer optional — it is the baseline. The SAFElife expanded-panel line offers four configurations that all include a dedicated fentanyl (FTY) analyte, along with EtG alcohol and other substances relevant to the Texas recovery population. The right cup depends on your program's risk profile, documentation requirements, and budget.

All four SAFElife expanded-panel cups include a dedicated fentanyl (FTY) analyte. Only the 14-panel is CLIA waived — the 12, 16, and 18-panel cups are Forensic Use Only (FUO). DrugScreens.com also carries additional CLIA-waived cup options for programs requiring clinical documentation for Medicaid billing or court records.

Building Fentanyl Testing Into Your Texas Recovery Protocol

Every intake, every compliance screen, every random test, and every post-relapse assessment at a Texas recovery program should now use a cup with a dedicated fentanyl analyte. The data from Texas DSHS and the One Pill Kills campaign is unambiguous: even with the encouraging 2024 decline, fentanyl remains the dominant driver of drug poisoning deaths in Texas at nearly 1,900 deaths in the most recent 12-month measurement period. The five-year surge that killed more than 7,000 Texans did not happen because recovery programs were not trying — it happened in part because the tools being used could not detect the substance causing the deaths.

This content is provided for general informational purposes only and does not constitute legal advice. Any employer or organization considering changes to its workplace or in-house drug screening policies should consult with qualified legal counsel and applicable regulatory authorities before implementing, modifying, or discontinuing any testing program or related procedures.